Mural Oncology to be Acquired by XOMA Royalty, Effective December 5, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Globenewswire
- Acquisition Approval: The High Court of Ireland has sanctioned the scheme of arrangement between Mural Oncology and its shareholders, allowing XRA 5 Corp. to acquire all issued shares of Mural, which is expected to enhance liquidity for Mural's shareholders by providing cash compensation effective December 5, 2025.
- Transaction Timeline: Mural shares are expected to cease trading on Nasdaq on December 4, 2025, with cash compensation distribution to shareholders anticipated to be completed by December 19, ensuring prompt access to funds and boosting shareholder confidence post-transaction.
- Legal Compliance: The acquisition adheres to Chapter 1 of Part 9 of the Irish Companies Act, ensuring the legality and transparency of the transaction, which mitigates potential legal risks and enhances market trust in Mural's future prospects.
- Market Reaction Anticipation: As the acquisition progresses, market interest in Mural is expected to rise, potentially attracting more investors to XOMA Royalty's strategic positioning, thereby further strengthening its market position in the biopharmaceutical sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
